Literature DB >> 30514613

Prevalence and diversity of filamentous fungi in the airways of cystic fibrosis patients - A Dutch, multicentre study.

Tobias G P Engel1, Lydie Slabbers2, Carmen de Jong2, Willem J G Melchers3, Ferry Hagen4, Paul E Verweij3, Peter Merkus2, Jacques F Meis5.   

Abstract

BACKGROUND: Progressive lung injury in Cystic Fibrosis (CF) patients can lead to chronic colonization with bacteria and fungi. Fungal colonization is obtained from the environment which necessitates locally performed epidemiology studies. We prospectively analyzed respiratory samples of CF patients during a 3-year period, using a uniform fungal culture protocol, focusing on filamentous fungi and azole resistance in Aspergillus fumigatus.
METHODS: Over a 3-year period, all respiratory specimens collected from CF patients in 5 Dutch CF centers, were analyzed. Samples were inoculated onto the fungal culture media Sabouraud dextrose agar (SDA) and Medium B+. All fungal isolates were collected and identified in one centre, using Amplified Fragment Length Polymorphism (AFLP) fingerprinting, rDNA PCR and ITS, calmodulin and β-tubulin sequencing. Azole resistance was assessed for all A. fumigatus using a qPCR assay followed by phenotypic confirmation.
RESULTS: Filamentous fungi were recovered from 699 patients from at least one respiratory sample, corresponding with 3787 cultured fungal species. A. fumigatus was cultured most often with a mean prevalence of 31.7%, followed by Penicillium species (12.6%), non-fumigatus Aspergillus species (5.6%), Scedosporium species (4.5%) and Exophiala dermatitidis and Cladosporium species (1.1% each). In total 107 different fungal species were identified, with 39 Penicillium species and 15 Aspergillus species. Azole resistance frequency in A. fumigatus was 7.1%, with TR34/L98H being the dominant resistance mechanism.
CONCLUSION: A vast diversity of filamentous fungi was demonstrated, dominated by Aspergillus and Penicillium species. We observed a mean azole resistance prevalence of 7.1% of A. fumigatus culture positive patients.
Copyright © 2018 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Aspergillus; Azole resistance; Cystic Fibrosis; Epidemiology; Filamentous fungi; Penicillium

Mesh:

Substances:

Year:  2018        PMID: 30514613     DOI: 10.1016/j.jcf.2018.11.012

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  25 in total

Review 1.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

2.  Evaluation of ID Fungi Plates Medium for Identification of Molds by MALDI Biotyper.

Authors:  Marie Gladys Robert; Charlotte Romero; Céline Dard; Cécile Garnaud; Odile Cognet; Thomas Girard; Tahinamandranto Rasamoelina; Muriel Cornet; Danièle Maubon
Journal:  J Clin Microbiol       Date:  2020-04-23       Impact factor: 5.948

Review 3.  Progress and challenges in fungal lung disease in cystic fibrosis.

Authors:  Gina Hong
Journal:  Curr Opin Pulm Med       Date:  2022-09-19       Impact factor: 2.868

4.  Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study.

Authors:  Axel Blomquist; Malin Inghammar; Mahasin Al Shakirchi; Petrea Ericson; Christina Krantz; Marcus Svedberg; Anders Lindblad; Lisa I Påhlman
Journal:  BMC Pulm Med       Date:  2022-07-05       Impact factor: 3.320

Review 5.  Emerging Fungal Threats in Cystic Fibrosis.

Authors:  C Schwarz; P Eschenhagen; J P Bouchara
Journal:  Mycopathologia       Date:  2021-07-28       Impact factor: 2.574

6.  Cathelicidin-inspired antimicrobial peptides as novel antifungal compounds.

Authors:  Martin van Eijk; Stephanie Boerefijn; Lida Cen; Marisela Rosa; Marnix J H Morren; Cornelis K van der Ent; Bart Kraak; Jan Dijksterhuis; Ivan D Valdes; Henk P Haagsman; Hans de Cock
Journal:  Med Mycol       Date:  2020-11-10       Impact factor: 4.076

7.  Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC).

Authors:  Sean X Zhang; N Esther Babady; Kimberly E Hanson; Amanda T Harrington; Paige M K Larkin; Sixto M Leal; Paul M Luethy; Isabella W Martin; Preeti Pancholi; Gary W Procop; Stefan Riedel; Seyedmojtaba Seyedmousavi; Kaede V Sullivan; Thomas J Walsh; Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

8.  Influence of relevant cystic fibrosis bacteria on Scedosporium apiospermum and Scedosporium boydii growth and viability.

Authors:  Andressa de Jesus Marques; Rodrigo Rollin-Pinheiro; Mariana Ingrid Dutra da Silva Xisto; André Luis Souza Dos Santos; Eliana Barreto-Bergter; Livia Cristina Liporagi-Lopes
Journal:  Braz J Microbiol       Date:  2021-01-13       Impact factor: 2.476

Review 9.  Fungal Infection and Inflammation in Cystic Fibrosis.

Authors:  T Spencer Poore; Gina Hong; Edith T Zemanick
Journal:  Pathogens       Date:  2021-05-18

10.  Clinician variability in the diagnosis and treatment of aspergillus fumigatus-related conditions in cystic fibrosis: An international survey.

Authors:  Gina Hong; Sameer Desai; Richard B Moss; Patience Eschenhagen; Bradley S Quon; Carsten Schwarz
Journal:  J Cyst Fibros       Date:  2021-07-29       Impact factor: 5.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.